Menu Search
Equities

Cordlife Group Ltd

CLIFF:PKC

Cordlife Group Ltd

Actions
  • Price (USD)0.2984
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-20.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 30 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cordlife Group Limited is a Singapore-based company that owns cord blood banks in Asia with full stem cell banking facilities in Singapore, Hong Kong, Indonesia, the Philippines, India and Malaysia. The Company’s segments include Banking and Diagnostics. The banking segment comprises the collection, processing and banking of biological materials. The diagnostics segment comprises diagnostics testing services. Its banking services include cord blood, cord lining, cord lining mesenchymal stem cells, corneal lenticule, cord lining epithelial stem cells, cord tissue and others. Its diagnostic testing services include newborn genetic screening, pediatric vision screening, pediatric ear screening, pediatric allergen test, genetic talent test, preimplantation genetic screening, endometrial receptivity test, non-invasive prenatal testing and newborn metabolic screening. Its MOMS UP is a mobile app offering pregnancy, as well as parenting resources for moms and moms-to-be in Asia.

  • Revenue in SGD (TTM)55.73m
  • Net income in SGD3.52m
  • Incorporated2001
  • Employees111.00
  • Location
    Cordlife Group Ltd1 Yishun Industrial Street 1A'Posh Bizhub, # 06 01 09 768160SingaporeSGP
  • Phone+65 62380808
  • Fax+65 62381108
  • Websitehttp://www.cordlife.com/sg/en/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.